Organisation paid for research Program year 2025 Source: CMS Open Payments

Bay Area Cardiology

Neither a doctor nor a teaching hospital

Research payments

$1,708,997

38 payments

Through program year 2025, Bay Area Cardiology is reported as receiving $1,708,997 in research payments, across 38 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $273,054 3
2024 Research $579,192 7
2023 Research $343,285 5
2022 Research $307,883 7
2021 Research $118,718 7
2020 Research $37,532 8
2019 Research $49,332 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $864,762 6 payments
  2. Merck Sharp & Dohme Corporation $513,714 9 payments
  3. Amgen Inc. $330,521 23 payments
Studies the money was for Research payments · program years 2019–2025
  1. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $864,762 6 payments
  2. A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF $513,714 9 payments
  3. 20170625-Vesalius - CV $77,465 2 payments
  4. 20170625_Vesalius - CV $62,697 4 payments
  5. Vesalius-Cv $49,332 1 payment
  6. (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States $38,824 4 payments
  7. Vesalius - CV $29,697 4 payments
  8. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke $28,458 1 payment
  9. OCEANa-Outcomes P3 CV $19,042 2 payments
  10. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) $14,856 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record